Halozyme Therapeutics (HALO) Other Non-Current Assets (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Other Non-Current Assets data on file, last reported at $50.9 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $50.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $50.9 million (changed N/A YoY), and the FY2025 annual result was $2.6 million, down 96.77% from the prior year.
• Other Non-Current Assets improved to $50.9 million in Q1 2026 per HALO's latest filing, from $2.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $80.6 million in Q4 2024 and troughed at $500000.0 in Q1 2022.
• A 5-year average of $24.3 million and a median of $17.6 million in 2024 frame the typical range for Other Non-Current Assets.
• On a YoY basis, Other Non-Current Assets climbed as much as 5160.2% in 2022 and fell as far as 96.78% in 2022.
• A 5-year view of Other Non-Current Assets shows it stood at $26.3 million in 2022, then sank by 51.3% to $12.8 million in 2023, then jumped by 529.26% to $80.6 million in 2024, then tumbled by 96.77% to $2.6 million in 2025, then soared by 1857.52% to $50.9 million in 2026.
• Business Quant data shows HALO's Other Non-Current Assets at $50.9 million in Q1 2026, $2.6 million in Q4 2025, and $17.9 million in Q3 2025.